UCSF Helen Diller Family Comprehensive Cancer Center

Institutional Humility & Engaging Diverse Communities in Cancer Research



KIM F. RHOADS, MD, MS, MPH, FACS ASSOCIATE DIRECTOR FOR COMMUNITY ENGAGEMENT UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER 1.28.2020

My background, training and experiences are diverse



BA '91: Linguistics MS '93-96: Health Sciences



MD '93-98 <u>Resident '98-'05: Surgery</u> Colorectal Fellowship '07 Health Policy Fellowship '08



MPH '06 Minority health disparities



Assistant & Associate Professor '08-'16 Board of Directors, Bay Area Black Women's Health Project ('93-'96)



Saturday School for Community Leaders ('95)



Community Based Participatory Research Training ('12)




Jeannette Barnes (1935-1993) Motivation for my work in health equity & disparities



- 58 years old
- Presented with a locally advanced breast mass (stage IIIB)
- Admitted for IV antibiotics; chemotherapy
- Died in the hospital (never having received palliative radiation therapy)

Disparities in Cancer are Longstanding



NCI website: <u>http://statecancerprofiles.cancer.gov</u> last access 3/1/2015

Traditional explanations for disparities in cancer survival focus on the individual

Patient Characteristics

- Chronic disease/comorbid states
- Late stage at diagnosis

Insurance Status

Lack of access to care contributes to poor outcomes


Genetic explanations

Racial/ethnic minorities have more aggressive tumors

Health disparities are a population level problem

No disparities in colon cancer survival within an integrated system

Kaplan-Meier Curves Comparing Survival by race/ethnicity in the integrated setting versus all other settings (Colon Cancer, stage I-III; California 2001-2006)




Rhoads KF & Patel MI. *JCO 2015*

Place Matters

WHERE YOU GO FOR CARE DETERMINES WHAT CARE YOU GET

Racial/Ethnic Diversity is Low in Cancer Clinical Trials, Nationally




Source: Baseline Study of Patient Accrual Onto Publicly Sponsored Trials," Coalition of Cancer Cooperative Groups for the Global Access Project, National Patient Advocate Foundation, April 2006. 'Lack of Trust' is an expected response to (historically) untrustworthy behavior

FOOD FOR THOUGHT

Magnitude of structural & physician and patient barriers to inclusion

Methods:


N=13 trials
N=8800 patients



Unger, et al. JNCI 2019


Magnitude of structural & physician and patient barriers to inclusion

Multi-level determinants of clinical trial inclusion



Unger, et al. JNCI 2019

Magnitude of structural & physician and patient barriers to inclusion



Unger, et al. JNCI 2019

Population level problems require system level solutions

Create Patient centered trial portfolios


Assess the match between available trials & patients

- Be intentional about the development of trial portfolios
- Cancer Centers need to increase the efficiency of opening trials
- Consider partnerships with community based care settings
 - These settings serve a higher proportion of racial/ethnic minorities
 - But have a higher proportion of mismatch (patients to trials)

Leverage institutional opportunities to make participation appealing & feasible

- Community Advisory Board—consultation on trial design/recruitment approaches; cultural tailoring of materials
- Patient Family Advisory Council— improving patient experience; reducing financial barriers, increasing financial transparency

The System Won't Change Unless We (Organize &) Demand It!



Institutional Humility & Engaging Diverse Communities in Cancer Research

THANK YOU!



